CRIS Current Research Information System

PANTANI, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.091
EU - Europa 2.037
AS - Asia 1.291
AF - Africa 180
OC - Oceania 6
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 6.610
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.074
IT - Italia 520
GB - Regno Unito 447
CN - Cina 421
SG - Singapore 342
SE - Svezia 329
VN - Vietnam 324
DE - Germania 251
IN - India 134
IE - Irlanda 105
RU - Federazione Russa 67
CI - Costa d'Avorio 64
FR - Francia 62
TG - Togo 60
UA - Ucraina 55
ZA - Sudafrica 39
EE - Estonia 32
BG - Bulgaria 31
FI - Finlandia 27
CH - Svizzera 26
BE - Belgio 21
JO - Giordania 18
CA - Canada 17
NL - Olanda 16
NG - Nigeria 15
AT - Austria 14
ID - Indonesia 11
IR - Iran 11
CZ - Repubblica Ceca 9
PH - Filippine 7
AU - Australia 6
ES - Italia 6
JP - Giappone 6
HK - Hong Kong 4
PL - Polonia 4
RO - Romania 4
LB - Libano 3
RS - Serbia 3
TR - Turchia 3
SC - Seychelles 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AR - Argentina 1
BD - Bangladesh 1
CL - Cile 1
CY - Cipro 1
EC - Ecuador 1
GR - Grecia 1
HR - Croazia 1
HU - Ungheria 1
KR - Corea 1
KZ - Kazakistan 1
LU - Lussemburgo 1
LV - Lettonia 1
MK - Macedonia 1
NO - Norvegia 1
PE - Perù 1
PT - Portogallo 1
SA - Arabia Saudita 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 6.610
Salva come PNG Salva come JPEG
Città #
Chandler 417
Southend 398
Fairfield 331
Singapore 295
Ashburn 265
Woodbridge 163
Bologna 159
Ann Arbor 148
Seattle 143
Dong Ket 136
Wilmington 136
Houston 130
Cambridge 113
Princeton 109
Dublin 105
Santa Clara 99
Boardman 81
Abidjan 64
Lomé 60
Beijing 59
New York 49
Nanjing 46
Bremen 45
Milan 43
Hyderabad 39
Westminster 38
Padova 33
Sofia 31
Turin 30
Jinan 29
Berlin 27
Redmond 27
Helsinki 26
Jacksonville 25
Shenyang 23
Fabriano 22
Redwood City 22
San Diego 22
Brussels 21
Saint Petersburg 21
Changsha 20
Amman 18
Bern 18
Florence 18
Los Angeles 16
Abeokuta 14
Medford 14
Nanchang 13
Zhengzhou 13
Hebei 12
Vienna 12
Falls Church 11
Jakarta 11
Rome 11
Guangzhou 10
Monmouth Junction 10
Washington 10
Dearborn 9
Jiaxing 9
Tianjin 9
Toronto 9
Wuhan 9
Des Moines 8
Mülheim 8
Norwalk 8
Amsterdam 7
Chengdu 7
Frankfurt am Main 7
Kuban 7
Olalla 7
Paris 7
Shanghai 7
Coimbatore 6
Hangzhou 6
Leawood 6
Munich 6
Taizhou 6
Boydton 5
Casalecchio di Reno 5
Kunming 5
Lanzhou 5
Riola 5
San Francisco 5
Tokyo 5
Anoia Superiore 4
Argelato 4
Como 4
Haikou 4
Hong Kong 4
Naples 4
Nuremberg 4
Parma 4
Phoenix 4
Porto Recanati 4
Romainville 4
San Lazzaro Di Savena 4
Taiyuan 4
York 4
Andover 3
Belgrade 3
Totale 4.506
Salva come PNG Salva come JPEG
Nome #
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease 217
Bortezomib-based therapy combined with high cut-off hemodialysis is highly effective in newly diagnosed multiple myeloma patients with severe renal impairment 198
Peripheral neuropathy induced by subcutaneous bortezomib-based induction therapy for newly diagnosed multiple myeloma. 186
Positron emission tomography with computed tomography-based diagnosis of massive extramedullary progression in a patient with high-risk multiple myeloma. 175
Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes 175
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. 172
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) 161
A 41-gene signature predicts complete response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) as induction therapy prior to autologous stem-cell transplantation (ASCT) in multiple myeloma (MM). 159
Thalidomide maintenance in multiple myeloma: certainties and controversies. 152
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 study. 151
Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma 148
A 41-Gene Signature Predicts Complete Response (CR) to Bortezomib-Thalidomide-Dexamethasone (VTD) As Induction Therapy Prior to Autologous Stem-Cell Transplantation (ASCT) in Multiple Myeloma (MM) 143
Current and emerging triplet combination therapies for relapsed and refractory multiple myeloma 142
Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy 139
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study 136
Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma 135
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 135
Opposite activation of the Hedgehog pathway in CD138+ plasma cells and CD138-CD19+ B cells identifies two subgroups of patients with multiple myeloma and different prognosis 134
Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens 133
Treatment optimization for Multiple Myeloma: schedule-dependent synergistic cytotoxicity of pomalidomide and carfilzomib in an in vitro and ex-vivo model 133
Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency. 128
Genomic characterization of the putative myeloma stem cells clone reveals alterations possibly correlated with the origin of disease. 127
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 127
Role of serum free light chain assay in the detection of early relapse and prediction of prognosis after relapse in multiple myeloma patients treated upfront with novel agents 122
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma. 122
High Number of Copy Number Alterations and Over-Expression of Genes Involved in the Response Mechanisms to Genotoxic Stress Both Characterize Newly Diagnosed Multiple Myeloma (MM) Patients Carrying Amplified MDM4 and/or Deleted p53 122
Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma 120
HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment 118
PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma 118
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 117
Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. 113
HIF 1 Alpha: A Suitable Target for Multiple Myeloma 110
Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis. 110
Maintenance therapy with bortezomib and dexamethasone after autotransplantation for high-risk multiple myeloma 110
Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma. 109
Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation 107
SIRT regulates the molecular interaction between c-MYC and HIF-1 alpha in multiple myeloma 104
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma 102
Gene expression analysis of newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted p5 101
null 98
Impact Of p53 Impaired Function On Outcomes Of Multiple Myeloma Patients Carrying Deleted TP53 and/Or Amplified MDM4 97
SIRT Regulates the Molecular Interaction Between c-MYC and HIF-1α in Multiple Myeloma 95
High CNA level and over-expression of genes involved in response mechanisms to genotoxic stress characterize newly diagnosed Multiple Myeloma (MM) patients carrying amplified MDM4 and/or deleted TP53 94
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 89
The Value of 18F-FDG PET/CT after Autologous Stem Cell Transplantation (ASCT) in Patients Affected by Multiple Myeloma (MM): Experience With 77 Patients 85
VarianThinker: a classification method to confidently approach the mutation heterogeneity in Multiple Myeloma 80
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 77
Identification of a Maturation Plasma Cell Index through a Highly Sensitive Droplet Digital PCR Assay Gene Expression Signature Validation in Newly Diagnosed Multiple Myeloma Patients 73
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma 63
The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases 60
Early Light Chains Removal and Albumin Levels with a Double Filter-Based Extracorporeal Treatment for Acute Myeloma Kidney 48
Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients 46
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 45
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 40
Proteasome inhibitors: Bortezomib in multiple myeloma 39
null 39
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 34
OAB-057: Temporal-weight estimation of the copy number alterations of of 1384 Multiple Myeloma patients defines an ancestrality index impacting patients survival 31
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 29
Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features 28
Circulating Multiple Myeloma Cells (CMMCs) as Prognostic and Predictive Markers in Multiple Myeloma and Smouldering MM Patients 27
The road to cure in multiple myeloma: Incorporation of novel agents into autologous stem cell transplantation 26
Rare, but complex chromosomal rearrangements, defined "Chromoanagenesis”, caused by single-step or stepwise catastrophic genomic events, significantly impact on Multiple Myeloma patients 23
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 23
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial 23
OAB-006: A novel algorithm to identify, characterize and define the prognostic impact of complex catastrophic events in Multiple Myeloma 21
High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients 21
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients 14
Abstract 2700: Negative selective pressure exerted by maintenance therapy promotes the extinction of sub-clones carrying high-risk lesions in multiple myeloma 13
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 13
Totale 6.805
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.025
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.025
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020736 0 0 0 0 0 0 153 163 166 102 64 88
2020/2021814 123 43 20 18 24 44 27 61 82 33 31 308
2021/20221.192 136 52 60 93 89 51 27 82 48 136 208 210
2022/20231.597 141 222 63 262 108 134 46 97 269 54 121 80
2023/2024604 41 83 34 51 47 152 27 84 13 19 31 22
2024/2025974 117 202 181 179 213 79 3 0 0 0 0 0
Totale 6.805